AbbVie Inc. (NYSE:ABBV) Declares Quarterly Dividend of $1.73

AbbVie Inc. (NYSE:ABBV) declared a quarterly dividend on Thursday, February 19th. Shareholders of record on Wednesday, April 15th will be given a dividend of 1.73 per share on Friday, May 15th. This represents a c) annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Wednesday, April 15th.

AbbVie has raised its dividend payment by an average of 0.1%per year over the last three years and has raised its dividend annually for the last 53 consecutive years. AbbVie has a dividend payout ratio of 49.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect AbbVie to earn $13.98 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 49.5%.

AbbVie Trading Down 2.0%

Shares of NYSE ABBV traded down $4.60 during trading hours on Thursday, hitting $224.13. 5,403,733 shares of the company traded hands, compared to its average volume of 7,512,111. The stock has a market capitalization of $396.12 billion, a price-to-earnings ratio of 94.97, a price-to-earnings-growth ratio of 0.81 and a beta of 0.35. The company’s 50 day moving average price is $224.01 and its 200 day moving average price is $221.68. AbbVie has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the previous year, the business earned $2.16 earnings per share. AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts anticipate that AbbVie will post 12.31 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ABBV. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. The Goldman Sachs Group reiterated a “neutral” rating and issued a $223.00 price objective on shares of AbbVie in a research report on Wednesday, January 28th. UBS Group cut their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research note on Thursday, February 5th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $258.00 price target on shares of AbbVie in a report on Thursday, January 15th. Finally, JPMorgan Chase & Co. increased their price objective on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $251.56.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.